Francisco Cervantes

发表

Mathematics in PreK: using digital resources to support early math learning and teaching

Naomi Hupert, Yelee Jo, Francisco Cervantes, 2014 .

The plausibility of using unmanned aerial vehicles as a serious game for dealing with attention deficit-hyperactivity disorder

Francisco Cervantes, Sonia López, Salvador Cervantes, 2020, Cognitive Systems Research.

Unexpected-Behavior Detection Using TopK Rankings for Cybersecurity

Francisco Cervantes, Alvaro Parres-Peredo, Ivan Piza-Davila, 2019, Applied Sciences.

Brain-Computer Interfaces for Controlling Unmanned Aerial Vehicles: Computational Tools for Cognitive Training

Francisco Cervantes, Salvador Cervantes, José-Antonio Cervantes, 2019, BICA.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Francisco Cervantes, Klaus Lechner, Thomas Fischer, 2003, The New England journal of medicine.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia.

Francisco Cervantes, Xabier Agirre, F. Prósper, 2007, Haematologica.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Francisco Cervantes, Jason Gotlib, Alessandro M. Vannucchi, 2017, Journal of Hematology & Oncology.

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

Francisco Cervantes, Sante Tura, Thomas J. Braun, 1984 .

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Francisco Cervantes, Giovanni Barosi, Viktoriya Stalbovskaya, 2012, The New England journal of medicine.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Francisco Cervantes, Alois Gratwohl, Giuseppe Saglio, 2006, Blood.

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2007, Leukemia research.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2013, Blood.

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Francisco Cervantes, Susan Branford, Andreas Hochhaus, 2017, The New England journal of medicine.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Francisco Cervantes, Thomas Fischer, Alois Gratwohl, 2006, The New England journal of medicine.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Francisco Cervantes, Wei Peng, Jason Gotlib, 2015, Haematologica.